For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 4,063,857 | |||
| General and administrative | 5,006,957 | |||
| Total operating expenses | 9,070,814 | |||
| Loss from operations | -9,070,814 | |||
| Change in fair value of warrant liability | -2,158 | |||
| Other income (expense), net | 155,007 | |||
| Total other income (expense), net | 157,165 | |||
| Net loss | -8,913,649 | |||
| Deemed dividends | 5,951,528 | |||
| Net loss attributable to common stockholders | -14,865,177 | |||
| Basic EPS | -23.95 | |||
| Diluted EPS | -23.95 | |||
| Basic Average Shares | 620,785 | |||
| Diluted Average Shares | 620,785 | |||
REVELATION BIOSCIENCES, INC. (REVBW)
REVELATION BIOSCIENCES, INC. (REVBW)